4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Vivoryon Therapeutics N.V. (VVY) operates in the Biotechnology industry and is headquartered in Halle, Germany with about 13 employees. Its market capitalization is roughly €33 million. In the fiscal year ended 2025-12-31, VVY reported €0M in revenue and (€9M) in net income.
Vivoryon Therapeutics N.V. operates as a clinical stage biopharmaceutical company that focuses on research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | €0M | €0M | (€4M) | €0M | — |
| Gross Profit | — | €0M | (€3M) | €0M | €9M |
| Operating Income (EBIT) | (€9M) | (€21M) | (€29M) | (€29M) | — |
| Net Income | (€9M) | (€21M) | (€28M) | (€28M) | — |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | €8M | €11M | €31M | €31M | — |
| Total Liabilities | €3M | €3M | €4M | €5M | — |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive VVY viewer.
About TickerBase · Data methodology & sources · Privacy · Terms